Bullet flag-united-kingdom flag-ireland


  • Respiratory

Understanding How Biomarkers Can Improve Asthma Care

Eosinophilic inflammation is a central to in Asthma pathogenesis. Blood eosinophils have been shown to be linked to rate of exacerbations and asthma control.1

In this webinar, Dr David Jackson explores the role of eosinophils in asthma, and the relationship between blood and sputum is discussed. Type 2 inflammation is highlighted in detail, and Type 2 cytokines are presented including interleukin IL-13 and fractional exhaled nitric oxide (FeNO).

The effects of inhaled corticosteroids on FeNO is also discussed, suggesting that FeNO guided management may lead to better outcomes than symptom-based management.2


1. Jackson DJ et al. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Advances in Therapy 2020; 37: 718-29.

2. Powell H et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2013; 378:983-990.

We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.

Dr David Jackson

Dr Jackson is a Consultant in severe asthma and eosinophilic lung diseases at Guy’s & St Thomas’ NHS Trust and leads the regional South Thames & Kent Asthma Network. He is an associate professor at King’s College London and leads a research group there investigating T2 inflammation and responses to biologic therapies in asthma and EGPA. He holds editorial positions at several respiratory journals, is a board member of GINA and is on the steering committee of the International Severe Asthma Registry (ISAR).